Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05174767

PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

Prospective, non-randomized, multicenter clinical investigation to assess the safety and effectiveness of AMDS in the treatment of patients with acute DeBakey type I dissection, with evidence of malperfusion, through open surgical repair.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Alabama at Birmingham, Birmingham, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥18 years of age or ≤80 years of age (male or female) at time of surgery
  • Acute DeBakey type I dissection based on computed tomography angiography (CTA) and diagnosed ≤14 days from of the index event
  • Presence of malperfusion (cerebral, visceral, renal, spinal cord, and/or peripheral)

Exclusion criteria

  • Other medical condition that is associated with limited life expectancy <2 years (e.g., cancer, congestive heart failure)
  • Pregnant or breastfeeding.
  • Unwilling to comply with the follow-up schedule
  • Institutionalized due to administrative or judicial order
  • Unwilling to accept blood transfusions for any reason
  • Coronary malperfusion
  • In circulatory shock (i.e., systolic blood pressure <90 mmHg) at time of screening
  • In extreme hemodynamic compromise requiring cardiopulmonary resuscitation at time of screening
  • Suspicion of bowel necrosis (as determined by the implanting physician based on imaging observations, peritoneal signs, surgical exploration, elevated serum lactate levels, low pH, and/or acidosis)
  • Clinical or radiographic signs of bowel infarction or gastrointestinal hemorrhage
  • Base deficit > -10 mmol/L or -10 mEq/L
  • American Society of Anesthesiologists risk class V (i.e., moribund patient not expected to live 24 hours with or without operation) or class VI (a declared brain dead patient whose organs are being removed for donor purposes)
  • Previous placement of a thoracic endovascular graft
  • Interventional and/or open surgical procedures 30 days prior to the dissection repair
  • Planned major interventional and/or open surgical procedures 30 days post the dissection repair
  • Systemic infection
  • Uncontrollable anaphylaxis to iodinated contrast (patients with allergy to iodinated contrast but not anaphylaxis may be eligible with appropriate pre-medication, as deemed suitable by the Investigator)
  • Known allergy(ies) to nitinol and/or polytetrafluoroethylene
  • Inability to obtain CT angiograms for follow-up
  • Previously diagnosed with Marfan syndrome, Ehlers-Danlos syndrome, or Loeys-Dietz syndrome based on laboratory genetic testing
  • Diagnosed with acute myocardial infarction in the 30 days prior to the dissection diagnosis
  • Diagnosed with severe and catastrophic neurological complications in the 30 days prior to the dissection diagnosis (namely, obtundation or coma)
  • Current Stage 5 end stage chronic kidney disease (eGFR ≤ 15 mL/min)
  • History of bleeding disorder (i.e. hemophilia)
  • A primary entry tear that extends into the arch or distal to the left subclavian artery
  • Need for a total aortic arch replacement and/or repair, or reconstruction, of any part of the arch, and branch vessels (including extra-anatomic bypass of the branch vessels), for any reason as deemed necessary by the Investigator
  • Any pathology of mycotic origin
  • Aortic fistulous communication with non-vascular structure (e.g., esophagus, bronchial)
  • Extensive thrombus or calcifications in the aortic arch, as defined by CTA
  • Excessive tortuosity precluding safe passage of the AMDS, as defined by CTA
  • Descending thoracic aneurysm involving the proximal third (one-third) of the descending aorta and measuring >45 mm in diameter
  • Aortic arch aneurysm >50 mm in diameter

Treatment and study plan

AMDS

Device

AMDS Implantation

Primary outcomes

  1. Primary Endpoint to Assess Incidence of Major Adverse Events

    Time frame: Through 30 days

    Patients experiencing at least one of the following MAEs:

    • All-cause mortality (ACM)
    • New disabling stroke
    • New onset renal failure requiring dialysis
    • Myocardial infarction (MI)
  2. Primary Endpoint to Assess Distal Anastomotic New Entry (DANE) tears

    Time frame: Through 30 days

    Patients experiencing Distal Anastomotic New Entry (DANE) tears

Sponsors and collaborators

Lead sponsor

Artivion Inc.

Industry

Collaborators

  • Syneos Health

Registry information

Official study title

A ProspEctive, Single ARm, Multi-center Clinical InveStigation to EValuatE the Safety and Effectiveness of AMDS in the TREatment of Acute DeBakey Type I Dissection: PERSEVERE

Acronym: PERSEVERE

Important dates

Study start
2022
Primary completion
2023
Study completion
2029
First posted
Jan 3, 2022
Registry last updated
Jan 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.